Tardive dyskinesia (TD) is a movement disorder that may result from the use of dopamine receptor antagonists (DRAs) that can affect people of all ages but is more debilitating for the elderly. Vesicular monoamine transport type 2 (VMAT2) inhibitors are currently the drugs of choice for treatment of TD. This article comprehensively reviews the safety and efficacy of two VMAT2 inhibitors which were approved by the Food and Drug Administration (FDA) in 2017.
Jugo E. Treatment of Tardive Dyskinesia with Deutetrabenazine versus Valbenazine. University of Lynchburg DMSc Doctoral Project Assignment Repository. 2023; 5(2).
Available when accessing via a campus IP address or logged in with a University of Lynchburg email address.
Off-campus users can also use 'Off-campus Download' button above for access.